STLN · Starling Oncology, Inc.

The thesis

Starling Oncology's move into capitated cancer-care contracts is lifting gross profit faster than revenue, and the third-quarter 2026 report decides whether that turns into repeatable profit. The test is adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) inside management's $500,000–$1.5 million guidance for the quarter, with full-year guidance unchanged. As of 21 October 2026 the company had not confirmed a report date. StockAnalysis lists 12 November, other calendars list 11 November, and Yahoo Finance lists 9 November.

Capitation means the company receives a fixed monthly payment for each covered patient and pays for that patient's cancer care. Margins widen when medical costs run below the payment and shrink when they run above it.

The business picture has not changed since the last read. The shares closed at $6.63 on 20 October 2026, up from $6.46 on 19 October 2026. Company news and SEC filings show no new release, guidance change or 8-K since Needham raised its target on 14 October 2026. The move higher reflects demand for the shares ahead of the report rather than new evidence, and the report remains the deciding event.

The narrative is maturing: the last new financial numbers came on 6 August 2026. The fresh items since then are an 1 October conference-schedule release, Needham's 14 October target increase and, per Simply Wall St on 13 October 2026, an addition to the S&P Health Care Services Select Industry Index and the launch of a provider platform called Starling Nexus.

Bullish and bearish views on Starling Oncology, Inc.

The bull case on Starling Oncology, Inc. (STLN), in brief: Gross profit grew faster than revenue. The bear case: Profit is thin and recent.

Bull case

• Gross profit grew faster than revenue. The 6 August release reported second-quarter 2026 revenue of $161.3 million, up 34.6% year over year, and gross profit of $27.2 million, up 55.2%. Investing.com's call coverage put the revenue against a $155.2 million analyst forecast.
• Guidance moved up in August. The same release raised FY2026 revenue guidance to $650–670 million from $630–650 million and gross profit guidance to $105–110 million from $97–107 million. Adjusted EBITDA guidance narrowed to $2–7 million from $0–9 million.
• Adjusted EBITDA turned positive. Second-quarter 2026 adjusted EBITDA was $229,000 against a $4.1 million loss a year earlier, per the 6 August release.
• Capitated revenue is set to double. The 6 August release guided to about $150 million of capitated revenue in 2026. Chief Financial Officer Rob Carter described a $300 million 2027 capitated-revenue outlook at the Wells Fargo Healthcare Conference on 8 September 2026, tied to Florida and California expansion and new Nevada and Oregon contracts.
• Every covering analyst rates it a buy. StockAnalysis showed five Buy ratings on 15 October 2026, a $9.40 consensus target and a range from Noble Financial's $8.00 to B. Riley's $11.00. Needham's Matthew Shea raised his target to $9 from $7 on 14 October 2026, per Benzinga.
• Debt maturities pushed out. Simply Wall St reported on 8 August 2026 that a new term loan moved major maturities to 2031. The 6 August release showed $41.1 million of cash.

Bear case

• Profit is thin and recent. The $229,000 second-quarter adjusted EBITDA came with a $9.8 million net loss, per the 6 August release. One positive quarter is too small a sample to show durable profit.
• Medical costs are already rising. Simply Wall St reported on 8 August 2026 that the medical loss ratio on capitated members, the share of contract revenue spent on care, rose to 85.5% from 71% a year earlier. Management's 2026 outlook range is 80% to 90%, so the ratio sits in the upper half.
• Patient-services profit fell. The same Simply Wall St report put second-quarter patient-services gross profit at $2.1 million, down from $4.7 million a year earlier.
• The Florida contract start slipped. Management said on the 6 August 2026 call that the Florida statewide contract moved from the third quarter to the fourth, per Investing.com's transcript. The third-quarter guide already depends on ramping Florida delegated lives.
• Insiders have been selling. Simply Wall St flagged significant recent insider selling on 13 October 2026, with insiders owning 12.8% of the company. SEC Form 4 filings include an insider transaction report dated 17 August 2026.
• Pharmacy dominates the revenue mix. Specialty pharmacy supplies most company revenue and grew 58% in the second quarter, per Investing.com's call coverage. Headline revenue growth therefore says little about capitated-care economics on its own.

Price setup

The shares closed at $6.63 on 20 October 2026, 6.0% under the 52-week high of $7.05 in adjusted daily closes. They rose 30.8% over the three months to 20 October 2026. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 54.8, which is neutral and well short of overbought.

Two closes anchor the recent range. The shares closed at $6.18 on 8 October 2026 and at $6.41 after the second-quarter report in early August. A close back under $6.18 would undo the October recovery, and a weekly close below $5.25 would put the shares under both reference points by a wide margin.

Crowding is moderate. All five covering analysts rate the shares a buy, insider selling has been reported, and the earnings report sits about three weeks out. The price is near the 52-week high without being stretched on RSI.

Catalysts, next 30 days

• ~12 November 2026 (est.): third-quarter 2026 results. StockAnalysis lists 12 November, other calendars 11 November and Yahoo Finance 9 November; the company has not confirmed. The report shows whether adjusted EBITDA lands in the $500,000–$1.5 million guide, whether the medical loss ratio stays at or under 90%, and whether FY2026 guidance holds.
• 19 November 2026: APG Fall Conference 2026. Dr. Podnos presents, per the company's 1 October release. This is the first scheduled management appearance after the report and may restate or revise the $300 million 2027 capitated-revenue outlook.

What would change the view

The case breaks if third-quarter adjusted EBITDA comes in below $500,000, if the medical loss ratio on capitated members rises above 90%, or if management cuts FY2026 revenue guidance of $650–670 million or adjusted EBITDA guidance of $2–7 million. A reduced 2027 capitated-revenue outlook or a further delay to the Florida statewide contract would also weaken it.

On price, a weekly close below $5.25 ends the thesis. That level sits under the $6.18 close of 8 October 2026 and the $6.41 post-earnings close of early August.

The case strengthens if the report lands at or above the top of the quarterly guide, with the medical loss ratio steady or lower and full-year guidance raised.

What it trades with

The shares trade mainly on company-specific results: guidance, contract starts and medical cost trends. Sentiment toward managed care and value-based care providers is the main outside influence, because insurers' and risk-bearing providers' reports on medical utilization shape how investors price capitated-risk contracts. Specialty pharmacy reimbursement is a second exposure, given that pharmacy supplies most revenue. The 13 October 2026 addition to the S&P Health Care Services Select Industry Index, reported by Simply Wall St, ties part of the share demand to funds tracking that index.